棕榈酸帕利哌酮治疗精神分裂症的疗效与安全性

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (680 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To evaluate the safety and efficacy of paliperidone palmitate in the treatment of schizophrenia. Methods 36 patients with schizophrenia were recruited as study group, while another 33 patients with the same diagnosis, same sex, age differences≤5 and PANSS score differences≤5 were as control group. The study group was given paliperidone palmitate by intramuscular injection every month; while the control group was given paliperidone tablets once a day per os, and the dose was gradually increased to 9 mg/d within one week. The PANSS score, efficacy and adverse events were observed in the two groups. Results The PANSS scores at different times before and after treatment in the two groups showed significantly differences (F=307.8, P<0.01) ; while the decreased score of PANSS between the two groups showed no significant difference (F=3.557, P=0.06); 24 weeks after treatment, 26 cases in the study group showed effecacy, with an effective rate of 81.3%, no case relapsed; 26 cases in the control group showed effecacy, 1 case recurred, with an effective rate of 84.4%, The difference of effective rate between the two groups was not statistically significant (P=0.740); the incidence of adverse events was no statistically significant (P=0.800). Conclusions The effecacy of paliperidone palmitate in schizophrenia is quite obvious, and is not inferior to oral paliperidone, and its adverse reactions are few, it is a good choice to use paliperidone palmitate as a treatment of schizophrenia.

Key words： paliperidone palmitate schizophrenia treatment

Received: 20 June 2014

ZTFLH:

R749.3

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Yingmei
	WANG Lina
	SUN Wenbin
	YANG Chunqiang

Cite this article:

LI Yingmei,WANG Lina,SUN Wenbin等. Efficacy and safety of paliperidone palmitate in treatment of schizophrenia[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2015, 26(2): 118-121.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2015/V26/I2/118

[1]	宓为峰, 邹连勇, 李梓萌, 等. 精神分裂症患者用药依从性及复发情况的调查[J]. 中华精神科杂志, 2012, 45(1): 25-28.
[4]	段武刚, 曾德志, 徐良雄, 等. 齐拉西酮和氯氮平治疗女性精神分裂症的疗效比较[J]. 海南医学院学报, 2010, 16(6): 771-773.
[2]	Sapra M, Vabia I V, Reyes P N, et al. Subjective reasons for adherence to psychotropic medication and associated factors among older adults with schizophrenia[J]. Schizophr Res, 2008, 106(2-3): 348-355.
[5]	McEvoy J P. Risks versus benefits of different types of long-acting injectable antipsychotics [J]. J Clin Psychiatry, 2006, 67(5): 15-18.
[3]	刘增龙, 崔利军, 苏丽惠, 等. 经络氧疗法联合利培酮治疗难治性精神分裂症对照研究[J]. 中国全科医学, 2010, 13(2): 546-547.
[4]	段武刚, 曾德志, 徐良雄, 等. 齐拉西酮和氯氮平治疗女性精神分裂症的疗效比较[J]. 海南医学院学报, 2010, 16(6): 771-773.
[5]	McEvoy J P. Risks versus benefits of different types of long-acting injectable antipsychotics [J]. J Clin Psychiatry, 2006, 67(5): 15-18.
[6]	Citrome L. Paliperidone palmitate-review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication[J]. J Clin Pract, 2010, 64(2): 216-239.
[7]	Keith S J, Kane J M, Turner M, et al. Academic highlights: guidelines for the use of long-acting injectable atypical antipsychotics[J]. J Clin Psychiatry, 2004, 65(1): 120-131.
[6]	Citrome L. Paliperidone palmitate-review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication[J]. J Clin Pract, 2010, 64(2): 216-239.
[8]	Nasrallah H. The case for long-acting antipsychotic agents in the post-CATIE era [J]. ActaPsychiatr Scand, 2007, 115(4): 260-267.
[9]	戴梅竹, 张钰成, 陈士华. 帕利哌酮联合帕罗西汀对精神分裂症阴性症状的影响[J]. 中国实用神经疾病杂志, 2013, 16(21): 81-82.
[7]	Keith S J, Kane J M, Turner M, et al. Academic highlights: guidelines for the use of long-acting injectable atypical antipsychotics[J]. J Clin Psychiatry, 2004, 65(1): 120-131.
[10]	Kramer M, Simpson G, Maciulis V, et al. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study[J].J Clin Psychopharmacol, 2007, 27(1): 6-14.
[8]	Nasrallah H. The case for long-acting antipsychotic agents in the post-CATIE era [J]. ActaPsychiatr Scand, 2007, 115(4): 260-267.
[9]	戴梅竹, 张钰成, 陈士华. 帕利哌酮联合帕罗西汀对精神分裂症阴性症状的影响[J]. 中国实用神经疾病杂志, 2013, 16(21): 81-82.
[11]	Sliwa J K, Bossie C A, Ma Y W, et al. Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidone[J]. Schizophr Res, 2011, 132(1): 28-34.
[10]	Kramer M, Simpson G, Maciulis V, et al. Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study[J].J Clin Psychopharmacol, 2007, 27(1): 6-14.
[12]	Li H, Rui Q, Ning X, et al. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia[J]. Prog Neuro-psychopharmacol Biol Psyc-hiatry, 2011, 35(4): 1002-1008.
[13]	刘文芳, 姜文亮, 付德兴, 等. 抗精神分裂症药帕利哌酮研究进展[J]. 中国医药, 2012, 7(4): 516-518.
[11]	Sliwa J K, Bossie C A, Ma Y W, et al. Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidone[J]. Schizophr Res, 2011, 132(1): 28-34.
[12]	Li H, Rui Q, Ning X, et al. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia[J]. Prog Neuro-psychopharmacol Biol Psyc-hiatry, 2011, 35(4): 1002-1008.
[13]	刘文芳, 姜文亮, 付德兴, 等. 抗精神分裂症药帕利哌酮研究进展[J]. 中国医药, 2012, 7(4): 516-518.

[1]	. [J]. Med. J. Chin. Peop. Armed Poli. Forc., 2019, 30(8): 645-650.